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non-small-cell lung cancer (NSCLC) using geﬁ tinib or docetaxel. Probability distribu-
tions for adverse events and life expectancy were obtained from the INTEREST
study. We used a docetaxel chemotherapy cost-study at ISSSTE and for geﬁ tinib 
we used the drug’s institutional price. Health state utility values for calculating
QALYs (Quality Adjusted Life Years) were derived from a recently published study
done with UK patients. A 3% annual discount rate was applied on a monthly basis
to all costs. Finally, a probabilistic sensitivity analysis was made varying the cost of 
chemotherapy. The model was run 25 times with 500 patients in each arm. Results
are presented in US dollars with an exchange rate of 13.5 MXN pesos for 1 US dollar. 
RESULTS: There was no clinical difference in life expectancy between geﬁ tinib (10.25
months) and docetaxel (10.14 months). Average QALY for geﬁ tinib cohort was 0.487 
(95% CI, 0.437 – 0.537) and for chemotherapy cohort was 0.438 (95% CI, 0.388 –
0.488). The average cost per patient treated with geﬁ tinib was $12,103 (95% CI, 
$11,916 – $12,290) and with docetaxel was $20,076 (95% CI, $19,866 – $20,286).
The acceptability curve shows a 100% dominace of geﬁ tinib over docetaxel, after a
chemotherapy price of $1,333. CONCLUSIONS: Geﬁ tinib is an alternative therapy 
for second line treatment of NSCLC that dominates docetaxel chemotherapy, in terms 
of quality of life related to reduced presence of adverse events, at a lesser cost to the 
institution.
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OBJECTIVES: Chronic myelogenous leukaemia (CML) is a progressive disease associ-
ated with a signiﬁ cant burden on both the patient and the health care provider. 
Although durable response from imatinib is achievable for many patients, some
develop resistance or intolerance. In these patients, other tyrosine kinase inhibitors 
(TKIs), such as dasatinib and nilotinib are treatment options. This study uses outputs
from recent clinical trials evaluating TKIs to predict the long-term economic and cost 
outcomes associated with different levels of best response. METHODS: A Markov
model was developed to estimate the costs and health outcomes associated with 
chronic, accelerated and blast phase CML. Short-term response was deﬁ ned as ‘no
response’ (NR), ‘complete haematological response’ (CHR), partial cytogenetic
response (PCR) and complete cytogenetic response (CCR). Resource use and quality-
adjusted life year (QALY) scores were stratiﬁ ed according to the patient’s current 
health status and response level. RESULTS: Patients in the chronic phase who achieve 
no response are estimated to experience a total of 1.50 QALYs and incur costs of 
a57,867 over their lifetime. Those who achieve CHR, PCR and CCR experience 3.47,
7.31 and 10.17 QALYs, and costs of a62,617, a66,499 and a67,117 respectively. In
the accelerated phase, the total number of QALYs for the NR, CHR, PCR and CCR
groups were 0.71, 1.70, 1.57 and 4.10 respectively. For the same groups, the lifetime 
costs were a35,273, a35,850, a35,886 and a51,693. In the blast phase, the QALY 
outcomes for the four groups were 0.18, 0.41, 0.63 and 1.46, whilst the costs were 
a13,252, a7,109, a10,993 and a25,501 respectively. CONCLUSIONS: There is a 
strong apparent relationship between short-term response to treatment and long-
term outcomes in CML. These ﬁ ndings are likely to be useful in assessing the cost-
effectiveness of existing treatments, whose short-term response is known, but where 
long-term data are currently unavailable.
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OBJECTIVES: To estimate the cost effectiveness of Posaconazole versus ﬂ uconazole/
itraconazole therapy in the prophylaxis against invasive fungal Infections among high-
risk neutropenic patients in Mexico. METHODS: A previously validated Markov
model was used to compare the projected lifetime costs and effects of two theoretical 
groups of patients, one receiving Posaconazol and the other receiving ﬂ uconazole/itra-
conazole. The model estimates total costs, numbers of IFIs, and QALY per patient in
each prophylaxis group. The model was extended with one-month Markov cycles in
which mortality risk is speciﬁ c to the underlying disease. Data on the probabilities of 
IFI were obtained from Study Protocol PO1899. Drug costs were taken from average 
wholesale drug reports for 2008. Cost and health effects were discounted at 5%. The
analysis was conducted from the Mexican health care perspective using 2008 unit cost
prices. RESULTS: Our model projects an accumulated cost to the Mexican health care
system per patient receiving the Posaconazol regimen of US$7463 compared to 
US$5634 for the ﬂ uconazole/itraconazole regimen. This results in an incremental cost
of –(US$1829) per patient. The accumulated discounted effect is 3.13 life years or 
2.25 quality adjusted life years (QALYs) per patient receiving Posaconazol, compared 
to 3.13 life years or 2.13 QALYs per patient receiving ﬂ uconazole/itraconazol. This 
translates into an incremental effect of posaconazole over ﬂ uconazole/itraconazole of 
0.17 life years gained (LYG) or 0.12 QALYs gained. The corresponding incremental 
cost effectiveness ratio (iCERs) is -(US$15,125) per QALY. Probabilistic sensitivity 
analysis tested numerous assumptions about the model cost and efﬁ cacy parameters
and found that the results were robust to most changes. CONCLUSIONS: The use of 
temozolomide in place of ﬂ uconazole/itraconazole for the prophylaxis against invasive
fungal Infections among high-risk neutropenic patients is likely to be cost saving. 
These conclusions are supported by the use of conservative assumptions and sensitivity 
analyses.
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OBJECTIVES: Patients receiving myelosuppressive chemotherapy are at risk for che-
motherapy-induced neutropenic complications (CINC). The study objective was to
examine the impact of CINC, deﬁ ned as neutropenia with fever or infection, on short-
term disability (STD) among cancer patients receiving chemotherapy. METHODS:
Patients with cancer undergoing chemotherapy were extracted from Thomson Reuters
MarketScan Commercial Database and Health and Productivity Management Data-
base. Patients were required to have at least 6 months continuous enrollment before 
the index date (ﬁ rst chemotherapy claim) and at least 30 days continuous enrollment
post-index date, full-time employment and eligibility for STD. Patients with ICD-9
codes for neutropenia and fever or infection and that had evidence of chemotherapy 
within 30 days prior were deﬁ ned as having CINC. Propensity score (PS) matching
was conducted for “CINC” and “non-CINC” patients based on demographic and
clinical characteristics, including chemotherapy class and use of highly myelosuppres-
sive chemotherapeutic agents. Subsequent multivariate regressions were conducted on
PS-matched cohorts to estimate the marginal impact of CINC: an Ordinary Least 
Squares Model on STD days, a generalized linear model on indirect cost associated 
with STD, and a logistic regression model on whether a patient used any STD days
during a month. RESULTS: A total of 280 CINC and 280 non-CINC patients were
PS-matched. Compared with matched non-CINC patients, CINC patients on average 
experienced 0.9 more STD day (3.2 vs. 2.3, p  0.046) which led to $156 more in
indirect costs ($549 vs. $394, p  0.050) per month. After multivariate adjustment,
CINC patients were 35% (p  0.121) more likely to experience at least one STD day,
experienced 1.0 more STD day (p  0.029), and incurred $200 more in indirect cost 
(p  0.016) per month. CONCLUSIONS: Patients with CINC experience signiﬁ cantly 
greater STD days than patients with no neutropenic complications from cancer che-
motherapy. Efforts that may prevent CINC can potentially have a beneﬁ cial impact 
on work absenteeism.
PCN76
REVISITING CHERNOBYL: THE LONG-RUN IMPACT OF THE NUCLEAR
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OBJECTIVES: The accident at the Chernobyl nuclear power plant in 1986 released 
an enormous amount of radioactive materials which spread over the territories of 
Ukraine, Belarus, Russia and other European countries. The damage caused to the
environment, economy and, most importantly, to human health has been challenging 
to estimate. In fact, there is no scientiﬁ c agreement on the severity of the Chernobyl
aftermath. The purpose of our paper is to investigate the long-run impact of the
tragedy on the labor market outcomes of the Ukrainian population. METHODS:
Speciﬁ cally, using data from 2001 household survey and a self-reported measure of 
well-being, we estimate the impact of the Chernobyl accident on individual earnings. 
In addition, we identify a substantial gender wage gap existing in the Ukrainian labor 
markets. We use the Oaxaca decomposition technique to examine the wage gap in 
more detail. RESULTS: We ﬁ nd that those individuals whose health has suffered as a
result of the accident receive on average 5% lower wages, after controlling for other 
characteristics. CONCLUSIONS: We ﬁ nd that a large portion of the wage gap is 
“unexplained” and may be attributed to discrimination against women; in addition,
the health effects of the Chernobyl accident explain a signiﬁ cant portion of the gender 
wage inequality.
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OBJECTIVES: After initial therapy with imatinib, chronic myelogenous leukemia 
(CML) patients who do not completely respond may require dose escalation or switch-
ing to another BCR/ABL kinase inhibitor to achieve the desired response. This study 
compared health care resource utilization associated with either escalation of imatinib 
dose or switching to dasatinib. METHODS: Two large administrative claims databases 
were combined (MarketScan and Ingenix Impact, January 1999–March 2008) to 
identify patients diagnosed with CML (ICD-9 code: 205.1). Patients initiated with 
imatinib who were continuously enrolled 6 months prior to and at least one month 
following their ﬁ rst dose increase or switch to dasatinib were selected. Patients who
switched to dasatinib before reaching imatinib 800 mg/day (switchers) and the non-
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switchers who increased imatinib dose to 400 mg/day (dose escalators) were then
followed until treatment discontinuation or end of eligibility. Negative binomial 
regression models were used to compare resource utilization associated with dose 
escalators vs. switchers, controlling for demographics, baseline imatinib treatment 
patterns, therapies, adverse events, and resource utilization. Cox regression models 
were used to study hospice services and stem cell transplants during the follow-up
period among patients without such prior event. RESULTS: Among CML patients 
who initiated on imatinib, 474 dose escalators and 175 dasatinib switchers were 
identiﬁ ed. Compared to dose escalators, switchers had signiﬁ cantly more frequent
inpatient visits (incidence rate ratio [IRR]  3.37, p  .005), emergency room visits
(IRR  1.80, p  .018), and outpatient visits (IRR 1.38 p  .001). Although low in
absolute rates, switchers had substantially higher risks of hospice use (hazard ratio 
[HR]  14.55, p  .066) and stem cell transplant (HR  8.71, p  0.006), indicating 
deteriorated clinical outcomes. CONCLUSIONS: Imatinib-treated CML patients who 
switched to dasatinib are associated with signiﬁ cantly more intensive resource utiliza-
tion and adverse clinical outcomes than those who escalated to higher doses. Further
studies are warranted to examine the causality of the differences in resource utilization
and clinical outcomes.
CANCER – Patient-Reported Outcomes Studies
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OBJECTIVES: In the present study, physicians’ beliefs about patients’ preferences 
regarding the treatment of MM were explored in a direct assessment and a Discrete
Choice Experiment (DCE) and were compared to the previously explored patients’
preferences. METHODS: In a preceding DCE with MM-patients, relevant attributes 
of an ideal MM-treatment were collected by reviewing the literature and by conducti-
ng a qualitative study with four focus groups. The attributes were analyzed in a
subsequent quantitative study using both a direct measurement (16 items on a
5-point Likert-scale) and a DCE (8 pairs with 8 characteristics). In the present 
study, 243 physicians answered (76% male, 62% haematology specialists, 70%
with 10 MM-patients in the last 12 months) the identical questionnaire. RESULTS:
Physicians rated physical quality of life (speciﬁ ed as “reduced mobility or good
mobility”), rare side effects and effectiveness aspects (duration of effect, maximal 
prolonged life expectancy and effectiveness) as most important attributes from the
patients’ perspective. While the direct assessment gathers a range of important aspects,
weighing particular relevant treatment attributes in a DCE is important. Physicians
ranked prolonged life expectancy as most relative important and signiﬁ cantly more
important than all other treatment attributes. Further treatment options were second 
most important and signiﬁ cant compared to breaks in therapy and physical quality of 
life, whereas the patients ordered these two top priorities reversely. CONCLUSIONS:
Over a broad range of treatment attributes the physicians’ perceptions of preferences 
were very close to those of MM patients. However in the DCE, after weighing the
attributes patients assigned a higher relative importance to further treatment options 
and “Not always think of the disease”, but less to prolonged life expectancy and 
self-application.
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NON-HODGKIN LYMPHOMA IN PATIENTS ATTENDED IN THE SOCIAL
SECURITY MEXICAN INSTITUTE
Balderas-Peña LMA1, Contreras-Hernandez I2, Mould-Quevedo J3, Garduño-Espinosa J2, 
Morgan-Villela G4
1Social Security Mexican Institute, pecialties’ Hospital. Western National Medical Center, 
Guadalajara, Mexico, 2Social Security Mexican Institute, Mexico City, Mexico, 3Pﬁ zer Mexico, 
Mexico City, Mexico, 4Social Security Mexican Institute, Guadalajara, Mexico
OBJECTIVES: The aim of this study was to describe health related quality of life in 
different stages of non-hodgkin lymphoma in patients attended in a tertiary referral
center at the Social Security Mexican Institute. METHODS: Were included outpatients 
with non-hodgkin lymphoma, attended in a tertiary referral center since July to 
August 2008, with the following inclusion criteria: older than 16 years, non-hodgkin 
lymphoma histological diagnosis, were included through informed consent; were
excluded patients with second malignant neoplasm or incomplete information. To 
calculate health related quality of life EORTC QLQ-C30 score validated Spanish
version to México was used; were evaluated global health status, functional scales
(physical, role, emotional, cognitive, social) and symptom scales (fatigue, nausea and 
vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, ﬁ nancial dif-
ﬁ culties) in scale since 0 to 100 (0  death, 100  perfect health). Were calculated 
means and range for EORTC QLQ-C30 score items; statistical differences were cal-
culated through ANOVA test, p value 0.05 was considered signiﬁ cant. RESULTS:
We studied 14 non-hodgkin lymphoma patients, mean age group was 60 o 12.3 years
old, 57% were women, 78% were married, and 23% had an educational level
of incomplete elementary school. The stating of this group was distributed as follow:
I-7%, II-14%, III-7% and NC (non classiﬁ ed)-72% (without complete histopathology
report at interview moment). Health related quality of life mean for all items was: 
I:88.2, II:87.6, III:48.11, according clinical stage in NC group was 75.1; p  0.23. 
The assumptions associated with a decreased health related quality of life associated 
with disease progression were emotional function (I-83, II-63, III-66; p  0.05), cogni-
tive function (I-10, II-83, III-50, IV-56; p  0.06). CONCLUSIONS: We observed a
decreased health related quality of life associated with a late clinical stage in emotional
and cognitive function.
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OBJECTIVES: The aim of this study was to describe health related quality of life
in different stages of breast cancer in patients attended in a tertiary referral center 
at the Social Security Mexican Institute. METHODS: Were included outpatients 
with breast cancer, attended in a tertiary referral center since July to August 2008,
with the following inclusion criteria: older than 16 years, breast cancer histological 
diagnosis, accepted were included through informed consent, were excluded patients 
with second malignant neoplasm or incomplete information. To calculate health 
related quality of life EORTC QLQ-C30 score validated Spanish version to México 
was used; were evaluated global health status, functional scales (physical, role, emo-
tional, cognitive, social) and symptom scales (fatigue, nausea and vomiting, pain, 
dyspnea, insomnia, appetite loss, constipation, diarrhea, ﬁ nancial difﬁ culties) in scale 
since 0 to 100 (0  death, 100  perfect health). Were calculated means and range for 
EORTC QLQ-C30 score items; statistical differences were calculated through ANOVA
test, p value 0.05 was considered signiﬁ cant. RESULTS: We studied 148 breast cancer
patients, mean age 51.68 o 10.32 years old, 69% were married, and 20% had an
educational level of preparatory school. The stating of this group was distributed 
according clinical stage as follow: I-6%, II-23%, III-16%, IV-7% without stage at 
interview moment (NC) 47% (ﬁ rst visit for diagnosis). Health related quality of life 
mean for all items was: I:85.7 o 7, II:75.36 o 15, III:74.47 o 17 and IV:61.05 o 22, 
NC:76 o 18 (p  0.07). The assumptions associated with a decreased health related 
quality of life in relation to late clinical stage were physical function (I-88, II-79, III-75, 
IV-56; p  0.003), role function (I-90, II-80, III-71, IV-43; p  0.001), weakness 
(I-83, II-66, III-62, IV-44; p  0.004) and pain (I-85, II-70, III-65, IV-50; p  0.05). 
CONCLUSIONS: We observed decreased health related quality of life in late clinical
stage. An important factor with impact in quality life could be adverse events related 
with adjuvant treatments.
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OBJECTIVES: The aim of this study was to describe health related quality of life in 
different stages of colorectal cancer in patients attended in a tertiary referral center at 
the Social Security Mexican Institute. METHODS: Were included outpatients with 
colorectal cancer, attended in a tertiary referral center since July to August 2008, with
the following inclusion criteria: older than 16 years, colorectal cancer histological 
diagnosis, accepted were included through informed consent; were excluded patients 
with second malignant neoplasm or incomplete information. To calculate health related 
quality of life EORTC QLQ-C30 score validated Spanish version to México was used; 
were evaluated global health status, functional scales (physical, role, emotional, cogni-
tive, social) and symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insom-
nia, appetite loss, constipation, diarrhea, ﬁ nancial difﬁ culties) in scale since 0 to 100
(0  death, 100  perfect health). Were calculated means and range for EORTC QLQ-
C30 score items; statistical differences were calculated through ANOVA test, p value 
0.05 was considered signiﬁ cant. RESULTS: We studied 31 colorectal cancer patients,
mean age patients was 55 o 11.5 years old, 54% were women, 71% were married, 
and 38% had secondary school. The stating of this group was distributed as follow: 
II-4 (13%), III-2 (6%) IV-7 (23%) and NC (non-classiﬁ ed)-18 (58%) (without complete
histopathology report). Health related quality of life mean according stage for all items 
was: II:57 o 22, III:86 o 12 and IV:66 o 14 NC 76 o 19 (p  0.17) The assumptions 
associated with a decreased health related quality of life associated with disease pro-
gression were pain (II-20, III-75, IV-52;p  0.02) and ﬁ nancial problems (II-25, III-100,
IV-76;p  0.09. CONCLUSIONS: We observed a decreased health related quality of 
life associated with late clinical stage by pain and ﬁ nancial problems.
